Lawsuit Alleges Iron Replacement Injection Resulted in Bone Pain, Fatigue and Other Problems From Low Phosphate Levels

According to allegations raised in a product liability lawsuit filed against the makers of Injectafer, side effects of the iron replacement injection caused a New York woman’s phosphate levels to become so depleted she developed a chronic condition that causes bone pain, fatigue and other serious health complications.

The complaint (PDF) was filed by Monique Benum and her husband, Eli, last month in the Court of Common Pleas in Pennsylvania.

Luitpold Pharmaceuticals, American Regent, Inc., Daiichi Sankyo and Vifor International are named as defendants in the lawsuit, which alleges Injectafer (ferric carboxymaltose) is so unreasonably dangerous that the risks far outweigh any potential benefits provided for users.

Learn More About

Injectafer Lawsuits

Side effects of the iron deficiency drug Injectafer may result in severely low phosphorous levels.


The iron replacement injection was first introduced in 2013, as a treatment for adults with anemia, who are not able to be treated with an oral iron supplement and have non-dialysis dependent chronic kidney disease. However, problems after Injectafer infusions have included reports of severe hypophosphatemia (HPP), which involves dangerous drops in phosphate levels and may lead to a number of severe health complications, including cardiac arrest, respiratory failure and death.

Injectafer is the only anemia treatment on the U.S. market which contains a unique ferric carboxymaltose (FCM) compound, which is known to cause severe HPP and potentially persistent HPP.

Benum indicates she was prescribed Injectafer for the treatment of iron deficiency anemia in June 2018, and received a total of 12 injections between June 25, 2018, and April 10, 2019. However, according to the lawsuit, her phosphate levels became “critically low” resulting in severe and/or symptomatic hypophosphatemia.

Although the drug makers knew or should have known about the risks associated with the Injectafer iron replacement treatment, warnings were withheld from users and the medical community about the risk of severe HPP, as well as the how the condition should be treated.

“Defendants at no times have attempted to warn users of these risks and have therefore violated their duties to warn and not misrepresent the benefits of a drug,” Benum’s lawsuit states. “Defendants also have a duty to explain to the medical community how to properly investigate and monitor a sharp drop in phosphorous levels. Defendants at no time have provided such warnings.”

Benum presents claims of negligence, failure to warn, design defect, negligent misrepresentation, fraud, strict liability, gross negligence, and her husband presents a claim of loss of consortium.

The case joins a growing number of other Injectafer lawsuits filed over the past year, each involving similar allegations of severe drops in phosphate levels after receiving the iron replacement injection.


Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL
Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL (Posted yesterday)

The U.S. District Judge presiding over all Suboxone lawsuits has created a mentorship program to use the litigation to provide some attorneys an opportunity to gain experience in handling complex federal multidistrict litigations.

Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M
Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M (Posted 3 days ago)

Gilead says it will pay $40 million to resolve HIV drug lawsuits over Truvada, Atripla, Viread, Stribild and Complera pending in the federal court system, involving claims that the the company sat on safer formulations of the drugs for years to increase profits.